Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

sHER-2 Human ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, HRP-labelled antibody
  • Other names:p185 ERBB2, C-erb B2, NEU-protooncogene
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


RAF101R 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

Sandwich ELISA, HRP-labelled antibody

Applications

Serum, Plasma-EDTA, Plasma-Heparin, Amniotic fluid, Cell culture supernatant

Sample Requirements

100 µl (1:20 prediluted)

Storage/Expiration

Store kit reagents between 2–8°C except controls. Store lyophilized controls at –20°C.

Calibration Curve

Calibration Range

0.16–10 ng/ml

Limit of Detection

0.06 ng/ml

Intra-assay (Within-Run)

CV = 1.9%

Inter-assay (Run-to-Run)

CV = 5.8%

Spiking Recovery

89,00%

Dilutation Linearity

95,00%

Summary

Research topic

Oncology

Summary

The human HER-2 (p158 HER-2, c-erbB-2, neu) gene encodes a putative transmembrane growth
factor receptor (p185 protein) that is closely related to the epidermal growth factor receptor
protein. The HER-2 gene product is a 185 kDa glycoprotein that contains an extracellular
ligand-binding domain and intracellular tyrosine kinase activity. HER-2 protein staining is
observed only in low levels in epithelial cells of most organs in normal human tissues and at
slightly higher levels in fetal tissues.
Both HER-2 oncogene amplification and oncoprotein overexpression have been analyzed for
potential utility in diagnostic and prognostic tests for: breast, ovarian, gastric, lung; and other
cancers. In these malignancies the HER-2 oncoprotein overexpression is correlated with
a poor prognosis.
In 15-40 % of primary breast cancers, amplification of the HER-2 oncogen is found which is
highly correlated with overexpression of the encoded 185 kDa protein and seems to play
a major role especially during the initiation of ductal carcinomas. HER-2 protein overexpression
is described as independent prognostic factor with greater predictive power than most
of the currently used prognostic tools - especially in axillary lymph-node-positive breast cancer
patients.
Studies analyzing small series of patients have suggested a prognostic value for HER-2
oncoprotein expression in axillary node negative (ANN) patients. An association between
oncoprotein expression and decreased overall survival among ANN patients with good nuclear
grade tumors has been demonstrated. In addition it has been reported that in low risk patients
(estrogen receptor positive, small tumors), HER-2 protein expression was associated with early
recurrence. Data demonstrate the large body of evidence implicating HER-2 oncoprotein
in the biology and prognosis of breast carcinoma.

References to Summary

References to HER-2

  • Evidence by in situ hybridization that c-erbB-2 proto-oncogene expression is a marker of malignancy and is expressed in lung adenocarcinomas. Am J Respir Cell Mol Biol. 1992 Sep;7 (3):325-34
  • . Expression of the ERBB2 protein in benign and malignant salivary gland tumors. Genes Chromosomes Cancer. 1991 Mar;3 (2):128-35
  • al-Kasspooles M, Moore JH, Orringer MB, Beer DG. Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int J Cancer. 1993 May 8;54 (2):213-9
  • Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 1990 Jul 1;50 (13):4087-91
  • Craven JM, Pavelic ZP, Stambrook PJ, Pavelic L, Gapany M, Kelley DJ, Gapany S, Gluckman JL. Expression of c-erbB-2 gene in human head and neck carcinoma. Anticancer Res. 1992 Nov-Dec;12 (6B):2273-6
  • Dittadi R, Donisi PM, Brazzale A, Marconato R, Spina M, Gion M. Immunoenzymatic assay of erbB2 protein in cancer and non-malignant breast tissue. Relationships with clinical and biochemical parameters. Anticancer Res. 1992 Nov-Dec;12 (6B):2005-10
  • Heatley M, Maxwell P, Whiteside C, Toner PG. C-erbB-2 oncogene product expression depends on tumour type and is related to oestrogen receptor and lymph node status in human breast carcinoma. Pathol Res Pract. 1993 Apr;189 (3):261-6
  • Kern JA, Schwartz DA, Nordberg JE, Weiner DB, Greene MI, Torney L, Robinson RA. p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res. 1990 Aug 15;50 (16):5184-7
  • Kynast B, Binder L, Marx D, Zoll B, Schmoll HJ, Oellerich M, Schauer A. Determination of a fragment of the c-erbB-2 translational product p185 in serum of breast cancer patients. J Cancer Res Clin Oncol. 1993;119 (5):249-52
  • Maguire HC Jr, Greene MI. The neu (c-erbB-2) oncogene. Semin Oncol. 1989 Apr;16 (2):148-55
  • Ohguri T, Sato Y, Koizumi W, Saigenji K, Kameya T. An immunohistochemical study of c-erbB-2 protein in gastric carcinomas and lymph-node metastases: is the c-erbB-2 protein really a prognostic indicator?. Int J Cancer. 1993 Jan 2;53 (1):75-9
  • Osaki A, Toi M, Yamada H, Kawami H, Kuroi K, Toge T. Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients. Am J Surg. 1992 Oct;164 (4):323-6
  • Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger J, Lippman ME, King CR. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol. 1990 Jan;8 (1):103-12
  • Paterson MC, Dietrich KD, Danyluk J, Paterson AH, Lees AW, Jamil N, Hanson J, Jenkins H, Krause BE, McBlain WA, et al. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res. 1991 Jan 15;51 (2):556-67
  • Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist. 2003;8 (4):307-25
  • Rubin SC, Finstad CL, Wong GY, Almadrones L, Plante M, Lloyd KO. Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis. Am J Obstet Gynecol. 1993 Jan;168 (1 Pt 1):162-9
  • Sato K, Moriyama M, Mori S, Saito M, Watanuki T, Terada K, Okuhara E, Akiyama T, Toyoshima K, Yamamoto T, et al. An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer. 1992 Nov 15;70 (10):2493-8
  • Seidman JD, Frisman DM, Norris HJ. Expression of the HER-2/neu proto-oncogene in serous ovarian neoplasms. Cancer. 1992 Dec 15;70 (12):2857-60
  • Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/n
Related Products Documents